Pulmonary Function After Non-Myeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.
A Parker RuhlRuba ShalhoubNeal JeffiresEmily M LimerickAlexis LeonardAmisha V BarochiaJohn F TisdaleCourtney D FitzhughMatthew M HsiehPublished in: Annals of the American Thoracic Society (2024)
and 6MWD in this predominantly adult cohort undergoing non-myeloablative HCT for SCD. Allogeneic HCT for SCD may cease the cycle of vaso-occlusive pulmonary injury and prevent continued damage. Multicenter studies are needed to evaluate the long-term lung health effects of HCT for SCD in adults and children.
Keyphrases
- sickle cell disease
- stem cell transplantation
- cell cycle arrest
- high dose
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- healthcare
- public health
- single cell
- pulmonary hypertension
- young adults
- oxidative stress
- cell death
- mental health
- cell therapy
- cross sectional
- health information
- clinical trial
- acute lymphoblastic leukemia
- acute myeloid leukemia
- low dose
- stem cells
- health promotion
- african american
- childhood cancer
- endovascular treatment